

The Division of Nuclear Medicine & Oncological Imaging within the university hospital of ULg is active in all fields of nuclear medicine, including SPECT/CT, PET/CT and therapeutics. It has been among the first hospitals to establish a clinical PET centre, in 1996.

Research axes & Expertise

- Clinical applications of FDG PET/CT imaging in non oncological indications, through strong collaborations with clinical departments, e.g. rheumatology, cardiovascular surgery, etc.
- PET/CT-guided radiation therapy treatment planning (Big Bore PET/CT device fully equipped for treatment planning)
- PET/CT imaging with alternative tracers

Application fields

The division offers a wide range of therapeutic applications, with 4 shielded rooms for ¹³¹I and ¹³¹I-MIBG treatments. Other treatments include radioimmunotherapy in lymphomas, metastatic bone pain palliation and selective intraarterial liver radiation therapy.

Major projects/partnerships/collaborations

- European project on nanomedicine: <http://www.erasmusmundus-nanofar.eu/>
- European project on aneurysmal disease: <http://www.fighting-aneurysm.org/>
- European project H2020-MSCA-ITN-2017 (PREDICT)

Key figures

11 FTE nuclear medicine physicians 2 FTE physicists 2 FTE radiopharmacists 2 PET/CT scanners, 9 gamma-cameras, including 2 SPECT/CT scanners

Publications: http://www.chu.ulg.ac.be/jcms/c_927987/publications-scientifiques

Contact

- Address: Service de Médecine nucléaire - Département de Physique médicale - CHU de Liège Sart Tilman B35 4000 Liège
- Website: www.chu.ulg.ac.be/jcms/c_11492/medecine-nucleaire
- Contact person: Pr Roland Hustinx -, rhustinx@chu.ulg.ac.be
- Phone: +32 43 66 71 99